晚期头颈部鳞状细胞癌患者的强化重组白细胞介素-2和α-干扰素治疗。
Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma.
作者信息
Urba S G, Forastiere A A, Wolf G T, Amrein P C
机构信息
Division of Oncology, University of Michigan Medical Center, Ann Arbor 48109.
出版信息
Cancer. 1993 Apr 1;71(7):2326-31. doi: 10.1002/1097-0142(19930401)71:7<2326::aid-cncr2820710725>3.0.co;2-h.
BACKGROUND
Cellular immune deficiency is a consistent finding in patients with advanced head and neck cancer. Interleukin-2 and alpha-interferon are modulators of the immune system.
METHODS
Eleven patients with recurrent head and neck cancer were treated in a Phase II study of recombinant human interleukin-2 (rIL-2) and alpha-2a-interferon (Roferon-A, Hoffmann-La Roche, Inc., Nutley, NJ). Each course consisted of rIL-2, 3 x 10(6) U/m2/day, as a continuous intravenous infusion over 24 hours for 4 days, and recombinant alpha-2a-interferon, 5 x 10(6) U/m2/day intramuscularly or subcutaneously daily for 4 days. This treatment was repeated weekly for 4 weeks, and then a second cycle was given after a 2-week break.
RESULTS
Two patients (18%) achieved a partial response. Toxic effects were substantial. Three of 11 patients experienced Grade 3 hypotension, 3 patients had Grade 3 oliguria, and Grade 3 fatigue was one of the most common reasons for withdrawal from the study. There were no deaths or need for intensive care monitoring.
CONCLUSIONS
In view of the 18% response rate, additional investigation of biologic therapy in advanced head and neck cancer is warranted.
背景
细胞免疫缺陷是晚期头颈癌患者的一个常见表现。白细胞介素-2和α干扰素是免疫系统的调节剂。
方法
11例复发性头颈癌患者参加了一项关于重组人白细胞介素-2（rIL-2）和α-2a干扰素（Roferon-A，霍夫曼-罗氏公司，新泽西州纳特利）的II期研究。每个疗程包括rIL-2，3×10⁶U/m²/天，持续24小时静脉滴注，共4天；以及重组α-2a干扰素，5×10⁶U/m²/天，肌肉注射或皮下注射，每日1次，共4天。该治疗每周重复1次，共4周，然后在休息2周后进行第二个周期。
结果
2例患者（18%）获得部分缓解。毒性作用显著。11例患者中有3例出现3级低血压，3例出现3级少尿，3级疲劳是退出研究的最常见原因之一。没有死亡病例，也无需重症监护监测。
结论
鉴于18%的缓解率，有必要对晚期头颈癌的生物治疗进行进一步研究。
Zotero 插件